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Metastasis to the thyroid gland (MTG) is rarely diagnosed clinically but the incidence 
of MTG at autopsy is not rare 
1-8
 (Table 1). Although the incidence of MTG at autopsy in 
unselected populations is low (0.5~2.8%), the incidence in populations with known primary 
cancers is reported to be much higher (3.9~24.2%). The most frequent primary sites are breast 
and lung.  
         The number of clinical cases with MTG has been gradually increasing 
9-12
, probably 
because of the development of various diagnostic techniques, including computed tomography 
(CT), F-18-fluorodeoxyglucose positron emission tomography (FDG-PET), 
13 
and fine needle 
aspiration biopsy (FNAB). 
12
 
 The treatment of MTG is controversial because the prognosis of these cases is 
basically poor, depending on the primary sites. Thyroidectomy for these patients is relatively 
invasive, and may not be effective in prolonging of survival time: however it may help preserve 
quality of life (QOL) in some circumstances because extension of MTG to surrounding tissues 
such as the trachea, esophagus, recurrent laryngeal nerve, or the larynx tends to worsen QOL. 
The decision to perform thyroidectomy may depend on the condition and needs of the individual 
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patient. The aims of this current report are to assess the clinical characteristics of MTG, and the 
role of thyroidectomy. We reviewed the charts of our patients with MTG who previously 
underwent thyroidectomy, and performed a literature review.  
 
Methods 
Patients who underwent thyroidectomy between 1988 and 2008 for MTG at the Kyoto 
University Hospital Department of Otolaryngology-Head and Neck Surgery were chart-reviewed. 
Patients with lymphoma or with tumors that directly invaded the thyroid from adjacent organs 
were excluded. Ultrasonography (US), CT, and FDG-PET were the preoperative imaging studies 
used for diagnosis. Cytological and histological diagnostic examinations were performed on 
biopsies from every patient. Metastatic cancer in the thyroid gland was confirmed by histological 
comparison of the thyroid specimen with the primary tumor. Immunohistochemistry of both 
primary and thyroid tumors was also performed if required. This study was approved by ethic 
committee of Kyoto University. 
 
Results 




Thyroidectomy was performed in 970 patients with malignant tumors of the thyroid. 
Four patients (1 male and 3 female) were diagnosed with MTG. Their ages ranged from 48 to 69 
years (median, 60 years) (Table 2). The incidence of MTG in thyroid malignancies was 0.4%. 
Each of the 4 patients had a different primary tumor, which included lung, liver, breast, 
and colon cancers, and each patient had undergone surgical resection and/or chemotherapy for 
the primary tumor before detection of MTG.  
 
Clinical presentation of metastasis to the thyroid gland 
Three of 4 patients were asymptomatic, and their MTGs were incidentally detected by 
follow-up FDG-PET or CT. None of the patients had thyroid tumor calcifications detected by US. 
One patient (case 3) presented with rapidly-growing thyroid nodules and skin redness involving 
the neck to the left precordial region because of invasive breast cancer in the left breast. The 
patient received steroid therapy for 1 week to prevent edema of the larynx but she gradually 
complained of dysphagia and dyspnea.  
The time to detection of MTG after primary tumor diagnosis ranged from 1 to 3 years. 
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All patients had concurrent nodal and distant metastases (lung or brain). 
Fine needle aspiration biopsies (FNABs) were used for diagnoses, which indicated 
adenocarcinoma in all cases: however it was difficult to definitively differentiate metastatic 
cancers from primary thyroid cancers. In 3 cases the diagnoses were further confirmed by 
postoperative immunohistochemistry.  
 
Treatment and prognosis 
Three patients underwent total thyroidectomy, and 1 patient (case 4) underwent 
subtotal thyroidectomy. There were no major postoperative complications observed, such as 
recurrent laryngeal nerve paralysis, hematoma, or respiratory distress. 
Three patients died from their primary disease 3 to 23 months after thyroidectomy, 
with a median survival time of 10 months. No patient developed cervical recurrences or 
respiratory symptoms. One patient (case 1 with lung cancer) has survived tumor-free for 1 year 
after thryoidectomy. She was treated with chemotherapy after thyroidectomy for intrapulmonary 
metastasis with complete resolution of the lung metastasis.  
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Representative case presentation (case 1) 
A 67-year-old woman underwent left upper lobectomy by video-assisted 
thoracoscopic surgery (VATS) for lung carcinoma. The pathologic diagnosis was 
adenocarcinoma with mixed subtypes (acinar and papillary), and was staged pT2N0M0. Two 
years later, a follow-up FDG-PET scan detected hypermetabolic lesions in the right lobe of the 
thyroid gland, as well as in the right upper lobe of the lung (Figure 1). The patient had no 
symptoms caused by the thyroid tumor. Physical examination revealed a hard 1 × 1 cm in the 
right lobe of the thyroid gland. Her regional cervical lymph nodes were not palpable. US and CT 
revealed a tumor without calcification in the right lobe of the thyroid gland (Figure 2A), and chest 
CT revealed 1 nodule in the right upper lobe of the lung without apparent lymphadenopathy, 
which corresponded to the same region of the FDG-PET findings (Figure 2B). Laboratory data 
revealed a serum carcinoembryonic antigen (CEA) of 1.3 ng/ml (normal range, 0-5.0). Free 
triiodothyronine (FT3) was 2.8 pg/ml (normal range, 2.3-4.0), and free thyroxine (FT4) was 1.04 
ng/dl (normal range, 0.8-1.6). Thyroid stimulating hormone (TSH) was 10.8 IU/ml (normal range, 
0.5-5.0) and thyroglobulin was 42.4 ng/ml (normal range, 0-45). FNAB cytology of the thyroid 
tumor revealed adenocarcinoma with papillary structure, which was suspicious for primary 
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thyroid tumor or lung cancer metastasis. 
After consultation with the thoracic surgeon, a total thyroidectomy was performed. 
Histology of the thyroid tumor showed papillary structures (Figure 3A). Immunohistochemically, 
the tumor cells were negative for thyroglobulin (Figure 3B) and positive for cytokeratin 19 (CK19) 
(Figure 3C), and the thyroid tumor was diagnosed as a lung cancer metastasis. 
Postoperatively, the patient was treated with gefitinib with good response. The lung 




The incidence of MTG has been thought to be very low. According to the report of 
Wychulis et al., 
9
 there were 10 cases with MTG out of 20,262 patients (0.05%) who underwent 
operation on the thyroid. The current case series also demonstrates a 0.4% incidence of MTG 
among patients undergoing thyroidectomy in our department over 20 years for a diagnosis of 
malignant thyroid tumor. According to the reports from Mayo clinic 
9-12
, however, the number of 
MTG cases has been gradually increasing. It is suggested that the recent development of 
Ishikawa M et al, Metastasis to the Thyroid Gland  
 
7 
diagnostic techniques such as CT, FDG-PET, 
13
 or FNAB 
12
 may improve the ability to detect 
MTG. 
The most frequent sites of primary malignancies metastatic to the thyroid are reported 
to be kidney, followed by breast and lung (Table 3). 
9-12,14-18
 Nakhjavani et al. 
15
 reported the 
frequency of kidney, lung, and breast primaries as 33%, 16%, and 16%, respectively. Our study 
also detected lung and breast cancers as the origin of metastasis in 1 patient each in addition to 
colon and liver cancer metastases. 
Metastasis to the thyroid gland is a clinical diagnostic problem. The reasons for this 
are thought to be as follows 
8
: (1) most patients are asymptomatic: (2) the sizes of the lesions are 
small in most cases: (3) a small sample size by FNAB makes a definitive pathologic diagnosis 
difficult: (4) the time to detection is long in some cases: and (5) the metastatic lesion is solitary in 
most cases. These reasons make differentiation from the primary thyroid tumor difficult.     
A malignant thyroid tumor is thought to be much more likely to be metastatic than 
primary in patients with a history of cancer. 
5
 It has been reported that an interval of 15 years 
elapsed from the diagnosis renal cell carcinoma to the detection of thyroid metastasis. 
17
 In our 
series, the time to detection ranged from 1 to 3 years. Therefore, it is important to include 
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metastasis to the thyroid gland in the differential diagnosis when a thyroid tumor is found in a 
patient with a history of cancer.  
It has been reported that a palpable thyroid nodule was found in 72% of patients with 
MTG. 
18
 The other 28% of patients were asymptomatic and a thyroid mass was incidentally 
detected by various imaging studies. However, as seen in case 3 in our series, there are some 
patients who complain of a rapidly-growing mass in the neck, dysphagia, or hoarseness. In these 
patients it is necessary to distinguish MTG from anaplastic thyroid tumors.  
US, CT, FDG-PET, and tumor markers specific to the primary tumor are useful 
diagnostic tools for early detection of MTG. Clinically FDG-PET has been frequently used for 
detection of recurrent cancer. In some cases, MTG is occult, and FDG-PET should be a useful 
imaging modality for these patients. Indeed, in case 1 we incidentally detected a thyroid tumor by 
FDG-PET.  
FNAB is also useful for the diagnosis. 
12
 We suspected MTG from the findings of 
FNAB in all the patients of this present series, but the diagnosis was not definitive. It is relatively 
difficult to accurately diagnose MTG by FNAB only, and it has been reported that the accuracy 
rate of FNAB for MTG was only 50%, although the percent of cases positive for malignancy was 





 Immunohistochemistry is a useful method for improving the accuracy of diagnosis, 
because metastasis to the thyroid gland can be distinguished from primary thyroid tumor by 
immunohistochemical demonstration of thyroglobulin. 
19
 However, 70~80% of anaplastic thyroid 
tumors are negative for thyroglobulin. 
20
  
Although thyroidectomy for MTG is recommended by some authors, 
14-16
 there is no 
clear consensus for therapy. One reason for this may be because the recommendations were 
based on case reports or uncontrolled studies. In a controlled study, 
18 
thyroidectomy was useful 
in preventing further dissemination of the primary tumor in patients whose metastases were 
limited only to the thyroid, although it did not contribute to prolonged survival. In addition, 
metastasis to the thyroid gland does not always mean poor prognosis, which depends on the 
dissemination and advanced stage of the primary tumor. In our series, thyroidectomy was 
performed for all of the MTG patients in order to prevent difficulty in respiration and/or swallowing. 
Although survival after thyroidectomy was poor in 3 of 4 cases, thyroidectomy was thought to 
contribute to maintaining QOL in respect to respiratory and swallowing functions. In addition one 
patient with lung cancer MTG remains alive without disease after thyroidectomy followed by 
chemotherapy.  
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In conclusion, it is still difficult to determine which patient with MTG is a good 
candidate for thyroidectomy, but we suggest that patients complaining of dysphagia or dyspnea, 




This study was supported in part by the grant from Takeda Foundation. 




1)  Rice CO. Microscopic metastases in the thyroid gland. Am J Pathol 1934; 10:407-12 
2)  Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 1000 autopsied 
cases. Cancer 1950; 3:74-85. 
3)  Hull OH. Critical analysis of two hundred twenty-one thyroid glands: study of thyroid glands 
obtained at necropsy in Colorado. AMA Arch Pathol 1955; 59:291-311. 
4)  Mortensen JD, Woolner LB, Bennett WA. Secondary malignant tumors of the thyroid gland: 
Cancer 1956; 9:306-9 
5)  Shimaoka K, Sokal JE, Pickren JW. Metastatic neoplasms in the thyroid gland: Pathological 
and clinical findings. Cancer 1961; 15:557-65. 
6)  Silverberg SG, Vidone RA. Metastatic tumors in the thyroid. Pacific Med Surg 1966; 
74:175-80.  
7)  Berge T, Lundberg S. Cancer in Malmo 1958-1969: An autopsy study. Acta Pathol Microbiol 
Scand Suppl 1977; 260:1-235. 
8)  Lam KY, Lo CY. Metastatic tumors of the thyroid gland: a study of 79 cases in Chinese 
patients. Arch Pathol Lab Med 1998; 122: 37-41. 
Ishikawa M et al, Metastasis to the Thyroid Gland  
 
12 
9)  Wychulis AR, Beahrs OH, Woolner LB. Metastasis of carcinoma to the thyroid gland. Ann 
Surg 1964; 160:169-77. 
10)  Czech JM, Lichtor TR, Carney JA, et al. Neoplasms metastatic to the thyroid gland. Surg 
Gynecol Obstet 1982; 155:503-5. 
11)  Ivy HK. Cancer metastatic to the thyroid: a diagnostic problem. Mayo Clin Proc 1984; 
59:856-59. 
12)  Smith SA, Gharib H, Goellner JR. Fine-needle aspiration: Usefulness for diagnosis and 
management of metastatic carcinoma to the thyroid gland. Arch Intern Med 1987; 147:311-12. 
13)  Sasaki M. An evaluation of FDG-PET in the detection and differentiation of thyroid tumours. 
Nuclear Med Comm 1997; 18：957-63. 
14) Rosen IB, Walfish PG, Bain J, et al. Secondary malignancy of the thyroid gland and its 
management. Ann Surg Oncol 1995; 2:252-56. 
15)  Nakhjavani MK, Gharib H, Goellner JR, et al. Metastasis to the thyroid gland: A report of 43 
cases. Cancer 1997; 79:574-78. 
16)  Chen H, Nicol T.L, Udelsman R. Clinically significant, isolated metastatic disease to the 
thyroid gland. World J of Surg 1999; 23:177-81. 




17)  Kim TY, Kim WB, Gong G, et al. Metastasis to the thyroid diagnosed by fine-needle 
aspiration biopsy. Clin Endocrinol 2005;  
62：236-41. 
18)  Papi G, Fadda G, Corsello SM, et al. Metastases to the thyroid gland. 
prevalence,clinicopathological aspects and prognosis: a 10-year experience. Clin Endocrinol 
2007; 66：565-71. 
19)  Burt A, Goudie RB. Diagnosis of primary thyroid carcinoma by immunohistological 
demonstration of thyroglobulin. Histopathology 1979; 3:279-86. 
20)  Hurlimann J, Gardiol D, Scazziga B. Immunohistology of anaplastic thyroid carcinoma: A 
study of 43 cases. Histopathology 1987; 11:567-80. 
 




Figure 1. Case 1. F-18-fluorodexoxyglucose positron emission tomography scan.   
Hypermetabolic lesions are seen in the neck (black arrow), and in the right lung (white arrow).  
Figure 2. Case1. Computed tomography scan showing tumor lesion in the right lobe of the 
thyroid (A, black arrow), as well as a tumor in the right upper lobe of the lung (B, black arrow). 
Figure 3. Histological findings of the thyroid tumor show (A) carcinoma with papillary structures 
(hematoxylin and eosin staining, ×40). (B) Immunohistochemistry shows negative for 
thyroglobulin in tumor cells while positive for normal thyroid tissue (×40). (C) Tumor cells are 
positive for cytokeratin 19 (×40) (black arrow). 
 
 
 
 
 
 
 









